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3Abstract
The diagnosis and management of allergy is complex; the clinical symptoms associated with allergic reactions 
span a broad spectrum of severity, from mild hay fever-type symptoms though to life-threatening anaphylaxis.  
Obtaining an allergy-focused clinical history is therefore vital for identifying possible allergic triggers and 
directing testing. However this focus could be changing as scientific and technological advances have paved 
the way for developments within in vitro testing for allergy.  With knowledge of allergens at the molecular 
level expanding, there are now the facilities to characterise the sensitisation profiles of allergy sufferers and 
determine the specific molecules (or components) against which the allergen-inducing immunoglobulin type 
E (IgE) proteins have been produced. This technology is termed component-resolved diagnostics (CRD). 
We know that accurate identification of IgE specificity, the source of the causative allergen and knowledge of 
potential allergic cross-reactivities are required for optimal clinical management of allergy patients. These 
factors can make allergy a diagnostic challenge outside of a specialist centre, and contribute to the difficulties 
associated with requesting and interpreting allergy tests. The incorporation of CRD into current practice has 
provided a platform for patient-tailored risk stratification and improved the application of allergen-specific 
immunotherapy, revolutionising specialist management of these patients. This review discusses the roles of 
each type of testing in allergy management, and predictions for future pathways.
Background
Allergy is an increasingly prevalent phenomenon in the population.  Allergy is typically associated with a small 
number of commonly encountered food types, pollens, drugs, and other sources.  The molecules within these 
substances that illicit allergic reactions are known as allergens.    (Laboratory approaches to assist in the 
diagnosis of allergic disease revolves around the detection of specific immunoglobulin E (sIgE), directed against 
likely causative sources of allergens based on an allergy-focussed patient history.  The allergens in these tests 
are mixed in nature, as an extract from an allergen source will contain many different molecules. . Advances 
in laboratory techniques have led to the development of tests that detect sIgE directed against molecularly-
defined allergenic components. The overarching term for this concept is component resolved diagnostics 
(CRD). The ability to distinguish between sIgE against unique components allows clinicians to identify true 
allergen sensitisation (production of sIgE towards a primary allergenic stimulus) from cross-reactivity (whereby 
sIgE against one allergen can bind to other allergens of similar molecular structure) with greater certainty. 
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4Following a recent survey into the use of CRD within allergy testing across the UK and Europe (1),  it was 
apparent that use of  CRD was becoming increasingly incorporated into routine diagnostics; however its clinical 
utility was potentially being compromised due to limited understanding and interpretive guidance for 
requesting clinicians. With wider implementation, the immunology laboratory must consider the practical 
aspects for CRD, both methodological and interpretative, prior to the introduction of these specialised tests. 
Given the need for an allergy-focussed patient history and the fact that CRD testing provides a wealth of 
complex allergomic data, we envisage that molecular allergology will remain in the specialist setting at the 
current time. However, in the future, allergy testing could be transformed with the assistance of artificial 
intelligence and machine learning algorithms that guide and direct primary care physicians through the 
complex interpretation of CRD and allergy diagnostics.
The aim of this article is to provide an overview of diagnostic allergy testing and to review the relevance of 
some of the recently introduced tests that require a clinical interpretation. It is outside the scope of this review 
to provide an in-depth evaluation on the applications of CRD.  Instead this review will provide an overview of 
the indications and advantages of using CRD in allergy diagnosis and management.  
The burden of allergy for healthcare
Allergic disease is one of the major causes of illness in developed countries and prevalence is increasing. The 
World Allergy Organisation (WAO) estimates that allergy prevalence of the whole population by country 
ranges between 10 - 40% (2). In Europe, an epidemiological review placed the prevalence of self-reported 
allergy at 17.3; thus nearly 1 in 5 people will experience some form of allergic reaction in their lifetime. In the 
UK, allergic disease affects about one in three of the population. In 13- to 14-year-old children, 32% report 
symptoms of asthma, 9% have eczema, and 40% have allergic rhinitis. The UK ranks highest in the world for 
asthma symptoms and is also near the top of the world ranking for allergic rhinitis and eczema. High and 
increasing trends are also apparent in nut allergy, anaphylaxis, occupational allergy (e.g. latex), and allergic 
reactions to drugs (3,4).  In the 20 years prior to 2012 there was a 615% increase in the rate of hospital 
admissions for anaphylaxis in the UK (5).
IgE-driven allergic reactions
The vast majority of proteins we are exposed to daily are well tolerated. However, in some individuals, IgE 
immunoglobulins are produced in response to innocuous ‘non-self’ proteins encountered from various animal, 
plant and microbial sources. These misdirected immune responses result in allergic reactions.
Allergic reactions driven by IgE have three characteristic stages: sensitisation, elicitation and late phase. During 
sensitisation, an allergen is recognised by the immune system, causing production of sIgE. The sIgE then 
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5circulates in the blood to sites of connective tissue (such as the skin and lungs) where they bind to the 
complementary high affinity IgE receptors on mast cells. In the elicitation phase, further exposure to the same 
allergen results in cross-linking of sIgE molecules bound to the IgE receptors through binding of the allergen 
to two adjacent sIgE molecules. This induces the mast cell to release proinflammatory mediators including 
histamine, tryptase, prostaglandins, leukotrienes and complement anaphylatoxins that cause the clinical 
symptoms associated with an allergic reaction. In late phase responses, further release of biochemical 
mediators and recruitment of eosinophils and basophils plays a key role in amplification of the allergic reaction 
(6,7).
The severity of allergic reactions is dependent upon the nature of the allergen, the susceptibility of the patient 
and the route of exposure. Mild symptoms may be limited to hives, rhinitis, or minor swelling (usually affecting 
the lips, tongue and orbital region); whereas severe allergic reactions can induce systemic anaphylaxis.  This 
variation provides a clinical dilemma in managing individual patients.  Patients whose allergic triggers and 
clinical symptoms are consistent with the potential to develop more serious complications requiring 
assessment from specialist services need to be distinguished from those patients who can be confidently 
managed in primary care. 
Exposure to allergic triggers
Allergens are most frequently encountered via ingestion, inhalation, or via a compromised skin barrier (Table 
1).  Food allergies elicit allergic reactions in the gastrointestinal (GI) tract upon consumption  (8) (9).  Airborne 
particles (e.g. pollen) cause allergic reactions in the respiratory system or upon contact with the eyes (10), 
whilst allergens that cross the skin barrier typically cause pruritic rashes and hives (11).  Each of these exposure 
routes may progress to systemic reactions including anaphylaxis.  The extent of allergic reaction is graded by 
severity of clinical manifestations (12).
The clinical approach to allergy diagnosis
In any patient with suspected clinical allergy, investigation is directed by a thorough allergy history which 
includes details of symptoms and time interval between exposure and onset of clinical symptom. Skin prick 
testing (SPT) is still a widely used diagnostic procedure and most commonly the first line investigative 
procedure used in allergy centres across Europe (13). These in vivo tests involve the cutaneous administration 
allergen extracts and the presence of a localised allergic response indicates a positive or negative result when 
compared with a control response.  SPTs have been shown to have high sensitivity for identifying sensitisation 
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6in oral challenge-positive individuals, compared with in vitro specific allergen testing (14,15), and are reliable 
tests for respiratory allergy (16). However, allergen panels for skin prick testing can vary considerably, and 
studies are limited by the availability of defined allergens (17). The lack of standardisation in the manufacturing 
of allergen extracts for use in skin testing has also recently been highlighted and is currently being addressed 
in Europe  (18,19). In addition, biological variation between patients affects the test performance. The 
sensitivity of skin testing is also affected by the threshold for positivity, and it is therefore vital that this is 
established locally based on equipment and technique or protocol used (20).
The laboratory approach to allergy diagnostics
Following an allergy-focussed patient history to identify potential triggers, and subsequent skin prick testing, 
the detection of specific IgE using in vitro methods, in particular allergen-specific IgE tests to allergen extracts 
are commonly used. The in vitro tests for specific IgE, as with in vivo SPT, use whole allergen extracts for 
analysis therefore are negatively affected by the heterogeneous nature of purified allergens. This problem is 
overcome through use of CRD, as the IgE being measured in this case is directed against separate allergen 
components, and therefore avoids any interference from minor or non-specific allergens.  These issues could 
have a significant impact on the usefulness of tests in clinical practice and highlight the need for specialised 
allergy services alongside a standardised approach when assessing patients, particularly when selecting 
patients for immunotherapy in consideration of test results. Whilst this approach remains clinically relevant 
for the routine mono-sensitised allergic patients, an improved diagnostic approach remains a clinical need, 
particularly for more complex cases which mainly arise due to the complexities of protein components of 
allergens, and their respective allergenicity. Subsequent testing using molecular-based allergen components 
may follow later, in an approach termed the ‘top-down’ diagnostic approach (21).
The increased availability and use of CRD is not only beginning to have an impact on the investigation of these 
challenging patients but is also unravelling further scientific understanding of the immunological signalling 
pathways involved in IgE-mediated hypersensitivity. Given the high levels of clinically variability observed 
between allergy patients, and even between patients with the same apparent allergy, it would appear that 
multiple factors and signalling pathways are at play following allergen binding and cross-linking IgE on the 
surface of mast cells and basophils, which can influence the overall clinical outcome. 
For example, the molecular data generated from undertaking CRD in patients with peanut allergy has enabled 
a level of risk stratification to be realised. This has improved diagnosis by introducing a more clear-cut decision 
points for peanut CRDs and has reduced the number of challenge tests undertaken in clinic (22). These changes 
are having significant consequences for the patient and, whilst the precise signalling pathways triggered 
following the binding of each peanut component to mast cell surface IgE have yet to be elucidated, it raises 
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7the question of whether a single common cell signalling pathway is activated for all allergens, or in fact 
multiple, cross-talking pathways are triggered depending on the inciting molecule(s). 
As we obtain more molecular data for allergens and begin to scratch the surface as to the signalling pathways 
activated, we have become aware that particular molecules within allergen proteins can exhibit a hierarchy or 
allergenic dominance, allowing risk stratification to be determined for certain allergies (23,24). However this 
now raises further questions as to whether the IgE-driven immune response triggered by every allergen 
follows a common sequence of signalling events in order to elicit the well-recognised allergic symptoms, or 
whether a hierarchy of allergen epitope dominance exists within allergen-driven signalling, which contains 
multiple cross-talking signalling pathways, activation of which is dependent on the particular allergen 
molecule-receptor binding. 
One way of deciphering this complex enigma is to utilise technologies including CRD, specifically ISAC allergen 
microarrays. ISAC microarray consists of 112 characterised allergens in a single test. This provides significant 
additional information which can be made available to clinicians, but the interpretation of which requires 
highly specialised expertise to be of clinical value. Most likely due to this limitation, it has not as yet been fully 
supported by current guidelines for management of allergy, but has been shown to have significant value in 
appropriately selected patients (25), in particular with respect to patterns of sensitisation, and idiopathic 
anaphylaxis.
Promoting the use of CRD and associated platforms such as ISAC in a controlled manner will potentially expand 
our knowledge of the allergic response pathways, and may uncover sensitisations that are as yet unknown. 
This should not be underestimated given the asymptotic nature of allergens that are yet to be characterised.
How can CRD help?
Allergen families & prediction of severity
Up to 90% of food allergies are caused by a group of animal and plant sources collectively known as the “Big 
8”: cow’s milk, eggs, peanuts, tree nuts (e.g. almonds, hazelnuts), fish, shellfish, soy and wheat (26). The same 
allergen source can elicit different types of allergic response amongst individuals. For example, peanuts can 
cause fatal allergic reactions in some individuals, whilst others only experience local mild reactions (27).
This variation can be attributed to specific allergenic components and their biochemical properties. Each 
source contains a number of different proteins, or allergen components, which can cause an allergic reaction; 
any two individual patients could be allergic to the same or different allergenic proteins within a source. 
Knowledge of the allergenic components linked to these reactions can help resolve the complex nature of 
allergy.
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8Components from different sources can be grouped into allergen families based on shared molecular 
characteristics (28).  Molecular analysis of the ~700 known allergens has demonstrated that the majority of 
allergens can be distributed into few protein families and possess a limited number of biochemical functions 
(29).  Determining the sensitising component, and its associated allergen family, can aid the clinician in 
determining the level of risk. This will ultimately improve the management of allergy patients; high-risk 
patients can be appropriately given and trained to use adrenaline injector pens, whilst reassurance can be 
given to lower risk patients, preventing unnecessary diet restrictions, anxiety, and referrals to tertiary care. 
Cross-reactivity between allergens from different sources is explained by the homogeneity exhibited within 
these protein families (30). High levels of cross-reactivity with other plant food allergens can result in allergic 
reactions when consumed (typically raw and/or unprocessed), despite not being originally sensitised to that 
source (31).The most prevalent plant-sourced allergens are distributed into distinct families: pathogenesis-
related (PR) proteins, profilins, prolamins such as non-specific lipid transfer proteins (nsLTP), and seed storage 
proteins. Figure 1 illustrates the major allergen components found in peanut (Ara h) and links them to their 
associated protein families; the individual components (and protein families) are depicted in order of risk 
severity.
Allergenicity (the potential to trigger an allergic response) is reflected in the molecular structure of an allergen, 
with relevant features such as size, solubility, stability, and conformation contributing to the ability of a 
particular molecule to trigger an allergic response (32). A primary allergen is the original molecule that induces 
sensitisation and production of sIgE. Cross-reactive allergens can cause allergic reactions to molecules present 
in different sources. Cross-reactivity occurs due to similarities between amino acid sequence homology and 
3D protein-folding of allergen components; shared structural conformations allow cross-reactive allergens to 
interact with IgE previously generated against the primary allergen, with the potential to induce an allergic 
response (32). Reactions to cross-reactive molecules may be less severe than the reactions to primary genuine 
allergens (21). 
Cross-reactivity also occurs due to post-translational glycosylation or cross-reactive carbohydrate 
determinants (CCDs) which exhibit similarity between different sources such as plants, venom proteins and 
house dust mites.  The production of sIgE against CCDs can give a broad sensitisation profile, causing multiple 
positive responses by SPT or in vitro IgE measurements (33). These cases can be difficult to interpret for the 
requesting clinicians; however as CCD do not usually associate with clinical symptoms, the ability to identify 
sensitisation to CCD can help eliminate clinically irrelevant positive results from true major allergen 
sensitisation.
Allergen molecules
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9Genuine or major allergenic molecules are classified as those causing species-specific sensitisation and 
subsequent IgE-mediated immune reactions to its corresponding allergen source for most allergic individuals. 
The definition of a major allergen is based on the prevalence of IgE or positive skin prick test to the total 
allergen extract however this does not take into consideration the allergenic risk for eliciting an immune 
response. Generally, in allergic patients major allergenic molecules bind to IgE and trigger responses in >50% 
of individuals with an allergy to its source, whereas minor allergens induce allergic reaction in <50% of allergic 
patients (21,34). 
For example, sensitisation to Bet v 1, the major allergen of Betula verrucos, (birch pollen), is found in over 90% 
of birch pollen allergy patients in Europe, with minor panallergen molecules Bet v 2 and Bet v 4 found to be 
responsible for sensitisation of 44.6% and 9.4 % of birch allergy patients respectively (35–37). The term 
‘panallergen’ refers to widely distributed ubiquitous protein molecules occurring across multiple species and 
allergen sources, and includes molecules such as profilins and calcium-binding proteins (31). The clinical 
relevance of panallergen sensitisation is considered limited, although can present problems if patients develop 
symptomatic multiple sensitives (38,39). The key aspect of all diagnostic allergy investigations, the allergy-
directed clinical history, will ultimately guide interpretation of serological results; however CRD can have a 
significant influence on future management options.
Clinical example: Pollen-associated food allergy/Oral allergy syndrome (Bet v 1 homologues)
A well-known group of cross-reacting plant allergens are the Bet v 1 homologues, belonging to the PR-10 family 
of proteins. As illustrated in figure 2, cross-reactive Bet v 1 homologues are found in a number of allergens 
from pollen, fruits, nuts, vegetables and legumes. Exposure, usually of raw, unprocessed allergen-containing 
foods, can result in a localised, symptomatic IgE-mediated allergic response in patients identified to have an 
allergy to birch pollen, driven by the major allergen Bet v 1. Using CRD to define primary sensitisation to PR-
10 allergen molecules can aid diagnosis of oral allergy syndrome. Furthermore, CRD can be helpful in 
identifying birch allergy patients with sensitisation to the minor allergen Bet v 2, thus potential cross-reactivity 
to components from the profilin family. As profilins are the most widely distributed proteins of the allergen 
families, cross-reactivity can occur from a wide range of unrelated species, including trees, weeds, grasses,  
fruits, vegetables and nuts, but will be distinct from those of the Bet v 1 homologues. Molecule-based 
approaches enable distinction between genuine sensitisation and the less clinically relevant IgE cross-
reactivity due to panallergens or carbohydrate determinants. Polysensitivity within birch allergy patients can 
also be identified using CRD; for which the determination of the primary sensitising source can help to direct 
appropriate management, including suitability for AIT.
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10
An official list of allergens is published by the WHO-International Union of Immunological Societies (IUIS) 
allergen nomenclature sub-committee (http://www.allergen.org).  This list currently contains approximately 
880 proteins, drawn from a variety of sources, each proven to have evidence of causing allergic reactions and 
IgE-binding capacity from the sera of at least 5 patients.  Allergen names are assigned by the allergen 
nomenclature sub-committee for consistent reproduction, compromising a reduced form of the taxonomic 
name (for example, peanut, Arachis hypogea, is abbreviated to Ara h), followed by a number to identify the 
protein family (40).
Diagnostic accuracy in polysensitisation and cross-reactivity
Allergy diagnosis is as complex as finding needle in a hay-stack. The patient may report several potential 
allergenic triggers and it’s often difficult to pin-point the exact culprit without detailed allergy-focused clinical 
history and the additional laboratory diagnostics. Although sIgE testing is widely used in clinical practice 
especially within primary care settings, the obtained serological results can often further complicate matters, 
particularly if sensitisation to several different allergens is detected (co- or polysensitisation). 
A major advantage of CRD includes assisting in the prediction of response by specifying ‘genuine’ as well as 
the ‘cross-reactive’ components in polysensitised individuals; such resolution is not possible using 
conventional testing.  This has been demonstrated for several allergens including food, pollen, venom and 
idiopathic anaphylaxis (39). Use of CRD in these patients not only improves the diagnostic accuracy but also 
provides additional information around individuals’ sensitisation profile which can assist risk stratification 
(illustrated in figure 1). Co-sensitisation is distinct from cross-reactivity, and occurs when IgE-driven responses 
are triggered by major allergenic molecules from two or more unrelated sources. The determination of 
genuine co-reactivity and cross-reactivity using CRD can have a significant impact on the interpretation of 
allergy results, particularly in complex cases whereby patients demonstrate presence of sIgE against multiple 
antigens. Major advantages of CRD include determination of the primary major allergen component (and 
protein family) to aid determination of reaction severity; the prediction of additional cross-reactivities and 
allergic reactions following exposure to sources containing molecular allergen homologues; and the 
identification of CCD-based cross-reactivity (which are unlikely to elicit reactions). 
Furthermore, there will be consequences for the appropriate administration of allergy immunotherapy; as 
responses will vary depending on whether genuine or cross-reactive allergen sensitisation is determined. 
Immunotherapy and scope for personalised treatment
Although exact immunological mechanism underlying the development of immune tolerance, and thus 
response to allergen-specific immunotherapy remains to be fully elucidated, it is accepted that the allergen 
component specificity to which the patient is sensitised plays a fundamental role (41). As highlighted earlier, 
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a considerable challenge for diagnostic investigations is associated with the extracts used to represent the 
allergen source. For both serological (in vitro) or skin-prick (in vivo) testing, these are traditionally based on 
crude extracts of the allergen source, and therefore contain a mixture of relevant and less clinically relevant 
allergen components. Immunotherapy products face a similar problem, in addition to the fact that 
standardisation of allergen concentration is usually only reported for major allergen molecules. This is likely 
to explain the variation in treatment responses between patients as some allergen molecules to which a 
patient is sensitised to will be poorly represented in the therapeutic product (42). In light of this, it is vital to 
identify the allergen components to which patients are responding to, as this will massively assist in 
anticipating the efficacy of treatment (43).
For instance, not all patients will be suitable candidates for immunotherapy as they will not be sensitised to 
the major allergens found in commercial immunotherapy extracts, or, due to heterogeneity between 
therapeutic extracts, the major allergens they are susceptible to are poorly represented (42). Prediction of 
treatment response using CRD would prevent inappropriate use of expensive immunotherapy in patients 
shown to respond to minor allergens, levels of which are found at much lower concentrations in commercial 
AIT (often unstandardized) and therefore are unlikely to induce allergen tolerance. CRD could also be used to 
reduce severe adverse responses during treatment. Some of the minor allergen components can be found in 
high concentrations within commercial IAT and sudden exposure on commencement of treatment could 
potentially trigger life-threatening anaphylaxis (44). These situations could be avoided if patients found to be 
sensitised to these molecular components can be identified prior to starting treatment.  
Further considerations for diagnostic allergy testing
In comparison with the heterogeneous nature of SPT and specific IgE tests, the products used in molecular 
component in vitro allergy tests are highly purified and the constituents of the component tests are fully 
characterised with no other minor antigens present. Single allergens are used (rather than multiple allergen 
extracts with varying compositions), and testing is carried out in laboratories where analytical performance is 
tightly regulated. However, due to the availability of allergens, the repertoire of these assays are restricted by 
the expansive existence of allergens which cannot feasibly be reflected in analytical tests using current 
methods (16,17).
Both SPT and in vitro diagnostic techniques are restricted in their use of allergenic source extracts.  By their 
nature, they are a mix of proteins and other molecules from an animal, plant or microbial source.  Thus 
detection of a positive response only identifies the source material, but not the specific protein to which the 
immune response has raised a specific IgE against.  This lack of specificity causes difficultly in accurately 
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identifying whether positive results are linked to reaction severity and predicting the likelihood of experiencing 
future allergic reactions to similar molecules in other allergenic sources (17,21).
An absence of international calibration standards for specific IgE assays, including allergen component testing, 
poses further analytical problems with inconsistencies, as a reference standard is only available for the 
measurement of total IgE (WHO 11/234). Instead, the units measured in sIgE assays are converted into 
quantitative sIgE antibody levels (kUA/l), using a reference curve calibrated to the WHO standard for total IgE. 
The assumptions made in the process (around the binding avidity and avidity of sIgE and allergen extract being 
comparable to the antibody binding when generating the total IgE reference curve) introduces one of many 
sources of error, resulting in potential quantitative inaccuracies up to 10% (45). These aforementioned factors 
have implications for laboratory testing and quantitation sIgE. Of particular importance, and relevant in order 
to achieve UKAS accreditation is the ability to define the measurement of uncertainty (MoU) within allergy 
diagnostics. Adherence to ISO 15189 laboratory standards requires that each laboratory must define their 
uncertainty budget for each analyte measured, meaning the inherent error of a result from analytical and 
biological differences. The lack of standardisation makes defining this measurement with confidence a 
challenge for laboratories. 
Multiple studies have also compared the performance of CRD with SPTs and challenge tests (gold standard 
provocation testing) for diagnosis of allergy, but a consensus has yet to be reached as the analytical 
performance varies depending on the allergen (17). When considering this in the clinical pathway, it would 
seem reasonable that both testing methods are used, particularly whilst there is an absence of appropriate 
clinical trials providing evidence of efficacy of treatment by allergen-specific immunotherapy based on 
components (17,21).
The future 
As with most diagnostic testing the immediate clinical context and past medical history are essential in order 
to interpret laboratory results. Often in the case of allergy, which is not monospecific, the presence of multiple 
reactivities to a range of allergens presents a diagnostic challenge. This is particularly evident when tests are 
requested by non-specialists such as general practitioners in the community. This lack of understanding often 
leads to wide variation in practice and inappropriate referrals to specialist allergy services and the greater use 
of emergency departments. The getting right first time (GIRFT) initiative (46) seeks to address these issues and 
improve the quality of care within the NHS. By reducing variation and promoting best practice it is predicated 
that there will be improved patients outcomes and opportunities for cost efficiencies. The challenge for allergy 
will be how best to support healthcare providers in the community given an ever increasing workload and 
limited time available for patient individual consultations. 
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The NHS Five Year Forward plan (47,48) identifies the need for more GPs who are supported by other 
professionals. It is hoped that this be will accelerated by partnerships between services in the community and 
hospital setting. How this might be achieved for allergy diagnostics remains unclear given the shortage of 
allergy specialists. It is apparent that the current ways of delivering education and information are struggling 
to have a significant impact which will continue until alternatives ways are established. This situation is likely 
to be compounded with the wider use of CRD. It is therefore important that new ways of delivering allergy 
services across integrated pathways are developed. Following the publication of the Industrial Strategy (49)  
and, in particular, the Health Sector deal (50) it is clear one such area might be the use of machine learning 
and artificial intelligence. The creation of case-based algorithms might provide opportunities for clinical 
standardisation and reduction in the unwarranted variation of allergy diagnostics. The use of machine learning 
and big data approaches might also provide a framework to support education across all healthcare providers 
potentially operating to a single governance structure. The use of exception rules provided by new cases would 
help refine the clinical utility of such an approach especially as new knowledge is uncovered by the wider 
adoption of CRD testing. Empowering patients to be more responsible for their care is a key objective in the 
NHS Five year Forward plan (48) and the greater use of artificial intelligence might offer a means by which this 
can be achieved on a large scale.
What does the future hold for the allergy patient? Given the growth in services available over the internet and 
the influence of social media it is especially likely that patients will continue to present well informed and 
potentially with a series of results from unconventional sources. Providing the healthcare provider, in 
whatever setting, with clear succinct information at the point of consultation will be central for providers of 
allergy tests to ensure the appropriate test is performed for the appropriate patient at the appropriate time
Conclusion/Summary
At the current point in time the application and routine use of CRD remain in its infancy, in need of immunology 
specialists, laboratories and requesting clinicians to evaluate the wealth of new evidence around their use in 
the absence of standardised protocols.  CRD will undoubtedly add value to understanding the IgE response on 
a molecular level in addition to expanding the current armoury of tests available for allergy investigation. The 
enhanced use of CRD by clinicians and allergy specialists is now required in order to obtain useful clinical and 
laboratory information in terms of sensitivity, specificity, PPV, NPV and risk assessment. This is evidenced in 
the wealth of recently published literature, however there is still a long way to go before CRD is being routinely 
used, confidently interpreted and adding value to individual patient cases on a regular basis.
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Table Legends:
Table 1: Common routes of exposure to allergenic proteins.  Protein allergens may be encountered by a 
variety of routes.  Severity of reaction is determined by type of allergen, its native integrity and the level of 
exposure.
Figure Legends:
Figure 1. Allergenic potential of peanut (Arachis hypogea) components. A number of proteins have been 
identified as allergens within the peanut. Identification of the specific component responsible for allergic 
sensitisation can help to guide clinicians in stratifying patients as high- or low-risk for systemic reactions. Image 
obtained from sources that permit free-to-use reproduction for commercial and non-commercial purposes.
Figure 2: IgE cross-reactivity of Bet v 1. The major birch pollen allergen, Bet v 1, is a PR-10 protein. Sensitisation 
to Bet v 1 is associated with cross-reactivity to one or more allergenic food sources that contain related PR-10 
proteins in over 70% of birch pollen allergy cases, causing oral allergy syndrome. Sensitisation to Bet v 2, a 
profilin protein, has a cross-reactive pattern of allergenic food sources distinct to that associated with Bet v 1. 
Identifying the specific allergenic component of birch pollen to which the patient has been sensitised can guide 
recommendations for avoidance of likely cross-reactive triggers of oral allergy syndrome caused by ingestion 
of foods with homologous PR-10 proteins. Reciprocal cross-reactivity between allergen components is 
demonstrated by double-headed arrows, and unilateral cross-reactivity is demonstrated by single-headed 
arrows. This figure was generated using the online Allergome O-ring tool (51); all images were obtained from 
sources that permit free-to-use reproduction for commercial and non-commercial purposes.
.
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